Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793990 | 0.86 | CHRM2 (0.43) | OPRM1OPRK1OPRL1CHRM1CHRM2 | |
| SCHEMBL2718551 | 0.81 | LMNA (0.51) | OPRM1OPRK1OPRL1CHRM1CHRM2 | |
| SCHEMBL5204992 | 0.80 | DAO (0.47) | OPRM1OPRK1OPRL1CHRM1CHRM2 | |
| SCHEMBL7220315 | 0.73 | DAO (0.44) | OPRM1OPRK1OPRL1CHRM1CHRM2 | |
| SCHEMBL3195760 | 0.71 | HTR7 (0.48) | OPRM1OPRK1CHRM1CHRM2CHRM3 | |
| SCHEMBL3195768 | 0.70 | HTR7 (0.53) | OPRM1OPRK1CHRM1CHRM2CHRM3 | |
| SCHEMBL319049 | 0.67 | CHRM1 (0.70) | OPRM1OPRK1OPRL1CHRM1CHRM2 | |
| SCHEMBL23832547 | 0.67 | LMNA (0.48) | OPRM1OPRK1OPRL1CHRM1CHRM2 | |
| SCHEMBL13081211 | 0.67 | OPRM1 (0.69) | OPRM1OPRK1OPRL1CHRM1CHRM2 | |
| SCHEMBL2722129 | 0.66 | OPRM1 (0.47) | OPRM1OPRK1OPRL1CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205292-B2 | Piperidines containing a lactam ring and a quinolinone, benzimidazolone, quinazolinone or benzodiazepinone group, e.g. N-[3R,7R)-1-(Cyclopropylmethyl)-2-oxo-7-phenylazepan-3-yl]-4-(2-oxo-1,4-dihydroquinazolin-3 (2H-yl)piperidine-1-carboxamide; treating headaches, migraine headaches and cluster headaches | MERCK & CO., INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20060194783-A1 | Cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194783-A1 | Cgrp receptor antagonists | BDKRB1, CCKBR, BDKRB2 | OPRM1 121/4885OPRK1 46/4885OPRL1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.